Skip to main content
. Author manuscript; available in PMC: 2021 Mar 10.
Published in final edited form as: J Urol. 2020 Apr 6;204(3):496–502. doi: 10.1097/JU.0000000000001064

Figure 1.

Figure 1.

Prostate cancer disease detection and prevalence of pelvic confined disease by 18F-DCFPyL PSMA targeted imaging in patients with biochemically recurrent prostate cancer. Percentage of 18F-DCFPyL PSMA targeted PET scans that detected prostate cancer stratified by absolute PSA (A) and PSADT (B). Prevalence of pelvic confined disease decreased with higher PSA (C) and shorter PSADTs (D).